Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study

ObjectivesThe causes of death among HIV-positive patients may have changed since the introduction of highly active antiretroviral therapy (HAART). We investigated these changes, patients who died without an AIDS diagnosis and factors relating to pre-AIDS deaths. MethodsAnalyses of 1826 deaths among EuroSIDA patients, an observational study of 8556 patients. Incidence rates of pre-AIDS deaths were compared to overall rates. Factors relating to pre-AIDS deaths were identified using Cox regression. ResultsDeath rates declined from 15.6 to 2.7 per 100 person-years of follow-up (PYFU) between 1994 and 2001. Pre-AIDS incidence declined from 2.4 to 1.1 per 100 PYFU. The ratio of overall to pre-AIDS deaths peaked in 1996 at 8.4 and dropped to < 3 after 1998. The adjusted odds of dying following one AIDS defining event (ADE) increased yearly (odds ratio, 1.53;P < 0.001), conversely the odds of dying following three or more ADE decreased yearly (odds ratio, 0.79;P < 0.001). The proportion of deaths that followed an HIV-related disease decreased by 23% annually; in contrast there was a 32% yearly increase in the proportion of deaths due to known causes other than HIV-related or suicides. Injecting drug users (IDU) were significantly more likely to die before an ADE than homosexuals (relative hazard, 2.97;P < 0.0001) and patients from northern/eastern Europe (relative hazard, 2.01;P < 0.0001) were more likely to die pre-AIDS than southern patients. ConclusionsThe proportion of pre-AIDS deaths increased from 1994 to 2001; however, the incidence of pre-AIDS deaths and deaths overall declined. IDU and subjects from northern/eastern Europe had an increased risk of pre-AIDS death. HIV-positive patients live longer therefore it is essential to continue to monitor all causes of mortality to identify changes.

[1]  P. Selwyn,et al.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. , 1992, The New England journal of medicine.

[2]  G. H. Mientjes,et al.  Increasing morbidity without rise in non‐AIDS mortality among HIV‐infected intravenous drug users in Amsterdam , 1992, AIDS.

[3]  C. Horsburgh,et al.  Survival prognosis of HIV-infected patients. , 1993, Journal of acquired immune deficiency syndromes.

[4]  D. Vlahov,et al.  Impact of HIV infection on non‐AIDS mortality among Italian injecting drug users , 1994, AIDS.

[5]  A. Mocroft,et al.  Staging system for clinical AIDS patients , 1995, The Lancet.

[6]  R. Coutinho,et al.  Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. , 1996, American journal of epidemiology.

[7]  Overall and cause-specific mortality in a cohort of homo-/bisexual men, injecting drug users, and female partners of HIV-infected men. Pulmonary Complications of Human Immunodeficiency Virus Infection Study Group. , 1996, AIDS.

[8]  R. Chaisson,et al.  Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.

[9]  Maria Prins,et al.  Pre‐AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users , 1997, AIDS.

[10]  R. Brettle,et al.  Pre-AIDS deaths in HIV infection related to intravenous drug use. , 1997, QJM : monthly journal of the Association of Physicians.

[11]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[12]  R. Brettle,et al.  Pre-AIDS mortality in the Edinburgh City Hospital HIV cohort. , 1997, Statistics in medicine.

[13]  J. Nielsen,et al.  Regional differences in use of antiretroviral agents and primary prophylaxis in 3122 European HIV-infected patients. EuroSIDA Study Group. , 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[14]  S. Darby,et al.  Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C , 1997, The Lancet.

[15]  P. Massip,et al.  Impact of protease inhibitors on AIDS‐defining events and hospitalizations in 10 French AIDS reference centres , 1997, AIDS.

[16]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[17]  B. Evans,et al.  Pre‐AIDS mortality in HIV‐infected individuals in England, Wales and Northern Ireland, 1982–1996 , 1998, AIDS.

[18]  K. Henry,et al.  Severe premature coronary artery disease with protease inhibitors , 1998, The Lancet.

[19]  A. Blaxhult,et al.  Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[20]  Broad welcome given to NHS white paper , 1998 .

[21]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[22]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[23]  R. Brettle,et al.  Mortality from overdose among injecting drug users recently released from prison: database linkage study , 1998, BMJ.

[24]  A. Mocroft,et al.  Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.

[25]  J. Kaldor,et al.  AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. , 1999, AIDS.

[26]  D. Cooper,et al.  Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: acohort study , 1999, The Lancet.

[27]  M Egger,et al.  AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. , 1999, JAMA.

[28]  C. Sabin,et al.  Pre-AIDS mortality and its association with HIV disease progression in haemophilic men, injecting drug users and homosexual men , 2000, AIDS.

[29]  A. Mocroft,et al.  AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.

[30]  C. Sabin,et al.  Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy , 2000, AIDS.

[31]  A. Mocroft,et al.  Regional differences in presentation of AIDS in Europe , 2000, Epidemiology and Infection.